The
Global CRO
for Biotechs

The full-service Contract Research Organization (CRO) with operations in Australia, New Zealand, Asia, North America, and Europe.

We specialize in delivering world-class operations, providing biotechs with strategic guidance from their early pre-clinical development with our experienced ClinicReady team through to late-phase studies, supported by our proven GlobalReady team. Our focus is on fast, agile, and adaptive operations that are solution-oriented, innovative, and cost-effective, ensuring rapid results and robust data.

With a proven track record and experience spanning across more than 120+ indications, Avance Clinical consistently delivers high-quality data that is accepted by global regulators, including but not limited to the TGA, FDA, MHRA, EMA, MFDS, PDMA.

Avance Clinical distinguishes itself by its commitment to personalized service rather than a one-size-fits-all approach.

FROST & SULLIVAN
BEST PRACTICES AWARD

FROST & SULLIVAN
BEST PRACTICES AWARD

Early Phase success

From comprehensive pre-clinical consultancy services through to phase one trials, we offer fast, agile and adaptive clinical research solutions for biotechs in the early phases of their drug development.

The ClinicReady team, our inhouse scientific and regulatory affairs experts, lay the vital clinical foundations that ensure seamless and successful transition into phase one and beyond.

Late Phase success

Our late phase operations deliver multi-regional clinical excellence across key therapeutic areas including oncology, CNS, rare diseases and infectious diseases. Our global teams apply decades of drug development experience, and leverage the latest technology, including AI and gold standard systems and processes, across all functional areas to deliver an exceptional CRO experience for biotechs.

Solutions

Bringing more than three decades of clinical operations experience.

WHY BIOTECHS
CHOOSE
AVANCE CLINICAL

Avance Clinical’s global teams have a world-class reputation for delivering quality data that is accepted by all the international regulatory authorities including FDA and EMA.

The Avance Clinical Technology & Innovation unit invests heavily in industry-leading as well as emerging technology platforms that elevate quality, speed, and cost metrics for our biotech clients. As part of this technology focus, Avance Clinical also has certified in-house platform specialists including Medidata trained experts.

Avance Clinical is one of the very few mid-sized global CROs with an in-house Scientific and Regulatory Affairs team delivering cross functional streamlined processes, and rapid and cost saving solutions.

Avance Clinical’s Australian operations can deliver Site Initiation Visit (SIV) and Study Start in 5 – 6 weeks. No IND is required. Indeed, more than 280 Phase III global trials conducted their Phase I in Australia. The 43.5% clinical trial rebate program can also extend to multi-regional later phases.

Latest News

Proven industry
experience & expertise

500+

Studies in the past 5 years

330+

Experienced team members

18k+

Participants past 5 years

30

Years of CRO experience